Abstract
Many tumor cells escape host-immune recognition by the down-regulation or lack of immunostimulatory molecules. Expression of immunostimulatory molecules on tumor cells by gene transfer can be used to induce an antitumor immune response. However, we have previously shown that protein transfer of glycosyl-phosphatidylinositol (GPI)-linked costimulatory molecules is a successful alternative to traditional gene transfer in preparing such a tumor vaccine. Vaccination with membranes modified by protein transfer to express GPI-linked B7.1 (CD80), a costimulatory adhesion molecule, induces protective immunity in mice and allogeneic antitumor, T-cell proliferation in humans in vitro. Our goal is to develop an optimal tumor vaccine using tumor membranes modified by protein transfer to target and stimulate antigen-presenting cells (APCs) and T cells. We have investigated the efficacy of expressing GPI-anchored cytokine molecules on the surface of tumor cells. Expression of interleukin-12 (IL-12) on tumor-cell membranes in a GPI-anchored form induces a strong antitumor immune response that is comparable to the effects of secretory IL-12. Because many cytokines act synergistically, we are testing the membrane expression and immunostimulatory effects of cytokines individually as well as in combination to determine potential complementary effects of coexpression on the antitumor immune response. Ultimately, the protein-transfer vaccination may be used in humans alone or in multimodal combination therapies to induce tumor regression and to serve as a protective measure to prevent postsurgical secondary metastases.
Article PDF
Similar content being viewed by others
References
Mayordomo JI, Zorina T, Storkus WJ, et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297–1302.
Kawashima I, Tsai V, Southwood S, Takesako K, Sette A: Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 1999;59: 431–435.
Tjandrawan T, Martin DM, Maeurer MJ, Castelli C, Lotze MT: Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother 1998;21:149–157.
Nestle FO, Alijagic S, Gilliet M, et al.: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328–332.
Alexander RB, Brady F, Leffell MS, Tsai V, Celis E: Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology 1998;51:150–157.
Celis E, Fikes J, Wentworth P, et al.: Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol 1994;31:1423–1430.
Tuting T, Gambotto A, DeLeo A, Lotze MT, Robbins PD: Induction of tumor antigen-specific immunity using plasmid DNA immunization in raice. Cancer Gene Ther 1999;6:73–80.
Tuting T, Gambotto A, DeLeo A, Lotze MT, Robbins PD, Storkus WJ: Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 1999;6:73–80.
Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL: Heat shock proteins come of age: primitive functions acquire new roles in adaptive world. Immunity 1998;8:657–665.
Yamazaki K, Nguyen T, Podack ER: Tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol 1999;163:5178–5182.
Guo Y, Wu M, Chen H, et al.: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994;263:518–520.
Townsend SE, Su FW, Atherton JM, Allison JP: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994; 54:6477–6483.
Pulaski BA, Ostrand-Rosenberg S: Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998;58:1486–1493.
Tahara H, Zitvogel L, Storkus WJ, et al.: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466–6474.
Levitsky HI, Montgomery J, Ahmadzadeh M, et al.: Immunization with granulocyte-macrophage colonystimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996;156:3858–3865.
Zitvogel L, Robbins PD, Storkus WJ, et al.: Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996;26:1335–1341.
McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P: Protein transfer of glycosylphosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res 1999;59:2433–2437.
Poloso N, Nagarajan S, Bumgarner GW, Selvaraj P: Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules. Vaccine 2001;19:2029–2038.
Nagarajan S, Selvaraj P: Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res 2002;62:2869–2874.
Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399–415.
Trinchieri G: Biological properties and therapeutic applications of interleukin 12. Eur Cyto Netw 1997; 8:305–307.
Mach N, Dranoff G: Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000;12:571–575.
Rosenberg SA: Lymphokine-activated killer cells: anew approach to immunotherapy of cancer. J Natl Cancer Inst 1985;75:595–603.
Tepper RI, Pattengale PK, Leder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503–512.
Brunda MJ, Luistro L, Warrier RR, et al.: Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993;178:1223–1230.
Nastala CL, Edington HD, McKinney TG, et al.: Recombinant IL-12 administration induced tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697–1706.
Dranoff G, Jaffee E, Lazenby A, et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539–3543.
Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998; 188:2357–2368.
Momann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348–2357.
McAdam AJ, Pulaski BA, Storozynsky E, et al.: Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-γ) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol 1995;165:183–192.
Trinchieri G: Biology of natural killer cells. Adv Immunol 1989;47:187–303.
Baccarini M, Schwinzer R, Lohmann-Matthes ML: Effect of human recombinant IL-2 on murine macrophage precursors. Involvement, of a receptor distinct from the p55 (Tac) protein. J Immunol 1989;142:118–125.
Trinchieri G, Scott P: Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol 1999;238:57–78.
Rosenberg SA, Lotze MT, Mule JJ: New approaches to the immynotherapy of cancer using interleukin-2. Ann Intern Med 1988;108:853.
Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA: High-dose recombinant interleukin 2 in treatment of patients with disseminated cancer. J Am Med Assoc 1986;526:3117–3124.
Rosenberg SA, Packard BS, Aebersold PM, Solomon D: Use of tumor-infiltrating lymphocytes and interlekin-2 in the immunotherapy of patients with metastatic melanoma. N Eng J Med 1988;319:1676.
Lotze MT, Matory YL, Ettinghausen SE, et al.: In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985;135:2865–2875.
Siegel JP, Puri RK: Interleukin-2 toxicity. J Clin Oncol 1991;9:694–704.
Leonard JP, Sherman ML, Fisher GL, et al.: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997;90:2541–2548.
Mule JJ, Shu S, Schwartz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984;225:1487–1489.
Yang JC, Rosenberg SA: Current approaches to the adoptive immunotherapy of cancer. Adv Exp Med Biol 1988;233:459–467.
Rosenberg SA, Yang JC, Schwartzentruber DJ, et al.: Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 1999; 163:1690–1695.
Mukherji B, Macalister TJ: Clonal analysis of cytotoxic T cell response against human melanomas. J Exp Med 1983;158:240.
Wang J, Saffold S, Cao X, Krauss J, Chen W: Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell—tumor fusion vaccines. J Immunol 1998;161:5516–5524.
Bhardwaj N: Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol Med 2001; 7: 388–394.
Fonteneau JF, Larsson M, Bhardwaj N: Dendritic cell-dead cell interactions: implications and relevance for immunotherapy. J Immunother 2001; 24: 294–304.
Dhodapkar MV, Bhardwaj N. Active immunization with dendritic cells. J Clin Immunol 2000; 20: 167–174.
Dhodapkar MV, Steinman RM, Sapp M, et al.: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999; 104: 173–180.
Banchereau J, Palucka AK, Dhodapkar MV, et al.: Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451–6468.
Mueller DL, Jenkins MK, Schwartz RH: Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989; 7: 445–480.
Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991; 173: 721–730.
Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL: CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med 1992; 175: 353–360.
Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993; 90: 6586–6590.
Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259: 368–370.
Baskar S, Ostrand Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH: Constitutive expression of B7 restores immunogenicity of tumor cells expressing trumcated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993; 90: 5687–5690.
Tan P, Anasetti C, Hansen JA, et al.: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165–173.
Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP: CD28 mediated signalling costimulate murine T cells and prevents induction of anergy in T cell clones. Nature 1992; 356: 607.
Porgador A, Gansbacher B, Bannerji R, et al.: Antimetastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer 1993; 53: 471–477.
Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E: IL-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217–1224.
Fearon ER, Pardoll DM, Itaya T, et al.: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397–413.
Li Y, McGowan P, Hellstrom I, Hellstrom KE, Chen L: Costimulation of tumor reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse mealoma. J Immunol 1994; 153: 421–428.
Baskar S, Glimcher L, Nabavi N, Jones R, Ostrand-Rosenburg S: Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995; 181: 619–629.
Wang Y-C, Zhu L, McHugh R, et al.: Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD80) costimulation. J Immunother 1996; 19: 1–8.
Nabel EG, Plautz G, Nabel GJ: Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. Med Sci 1992; 89: 5157–5161.
Ada GL: Vaccines. In Fundamental Immunology, 768th ed. (Paul WE, ed.). Raven Press, New York, 1993; pp. 1309–1352.
Davis HL, Demeneix BA, Quantin B, Coulombe J, Whalen RG: Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum Gene Ther 1993; 4: 733–740.
Simons JW, Jaffee EM, Weber CE, et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Hum Gene Ther 1997; 57: 1537–1546.
McHugh RS, Ahmed SN, Wang Y-C, Sell KW, Selvaraj P: Construction, purification and functional reconstitution on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA 1995; 92: 8059–8063.
Brunschwig EB, Levine E, Trefzer U, Tykocinski ML: Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. J Immunol 1995; 155: 5498–5505.
Selvaraj P, McHugh RS, Nagarajan S: Engineering GPI-anchored proteins. In MBIU 7: GPI-Anchored Membrane Proteins and Carbohydrates. (Hoessli D, Ilangumaran S, eds.). Landes Biosciences, Texas, 1999, pp. 197–211.
Nagarajan S, Selvaraj P: Reconstitution of CD16 expression on nucleated cells using purified CD16. FASEB J 1991; 5: A1718 (Abstract)
Nagarajan S, Anderson M, Ahmed SN, Sell KW, Selvaraj P: Purification and optimization of functional reconstitution on the surface of leukemic cell lines of GPI-anchored Fcγ receptor III. J Immunol Methods 1995; 184: 241–251.
Medof ME, Kinoshita T, Nussenzweig V: Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984; 160: 1558–1563.
Zhang F, Schmidt WG, Hou Y, Williams AF, Jacobson K: Spontaneous incorporation of the glycosyl-phosphatidylinositol-linked protein Thy-1 into cell membranes. Proc Natl Acad Sci USA 1992; 89: 5231–5235.
Huang JH, Greenspan NS, Tykocinski ML: Alloantigenic recognition of artificial glycosyl phosphatidylinositol-anchrored HLA-A2.1. Mol Immunol 1994; 31: 1017–1028.
Diamond DC, Finberg R, Chaudhuri S, Sleckman BP, Burakoff SJ: Human immunodeficiency virus infection is efficiently mediated by a glycolipid-anchored form of CD4. Proc Natl Acad Sci USA 1990; 87: 5001–5005.
Jasin M, Page KA, Littman DR: Glycosylphosphatidylinositol-anchored CD4/Thy-1 chimeric molecules serve as human immunodeficiency virus receptors in human, but not mouse, cells and are modulated by gangliosides. J Virol 1991; 65: 440–444.
Ferguson MAJ, Williams AF: Cell surface anchoring of proteins via glycosyl-phosphatidylinositol structures. Annu Rev Biochem 1988; 57: 285–320.
Low MG, Saltiel AR: Structural and functional roles of phosphatidylinositol in membranes. Science 1988; 239: 268–275.
van Broekhoven CL, Parish CR, Vassilou G, Altin JG: Engrafting costimulatory molecules onto tumor cell surfaces with chelator lipids: a potentially convenient approach in cancer vaccine development. J Immunol 2000; 164: 2433–2443.
Wahlsten JL, Mills CD, Ramakrishnan S: Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. J Immunol 1998; 161: 6761–6767.
Chen L, McGowan P, Ashe S, Johnston J, Hellstrom I, Hellstrom K: B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with corynebacterium parvum. Cancer Res 1994; 54: 5420–5423.
Pardoll DM, Topalian SL: The role of CD4+ T cell responses in antitumor immunity. [Review] [49 refs]. Curr Opin Immunol 1998; 10: 588–594.
Billadeau DD: ITAMs versus ITIMs: striking a balance during cell regulation J Clin Invest 2002; 109: 161–168.
Poloso NJ, Nagarajan S, Mejia-Oneta JM, Selvaraj P: GPI-anchoring of GM-CSF results in active membrane-bound and partially shed cytokine. Mol Immunol 2002; 38: 803–816.
Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998; 392: 245–252.
Zampell JC, Palaniswami P, Nagarajan S, Poloso N Selvaraj P: Interleukin-2 expressed as a cell surface molecule induces antitumor immune reponse in mice. FASEB J 2003 (Abstract).
Fukao T, Koyasu S: Expression of functional IL-2 receptors on mature splenic dendritic cells. Eur J Immunol 2000; 30: 1453–1457.
Verma UN, Mazumder A: Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differentiatl effects at different time points. Bone Marrow Transpl 1995; 16: 365–372.